FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093033478> ?p ?o ?g. }

• W2093033478 endingPage "1802" @default.
• W2093033478 startingPage "1795" @default.
• W2093033478 abstract "BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the Health ABC cohort (n = 2853). Significantly higher BMD was found in users of relative COX-2 selective NSAIDs with aspirin (COX-2/ASA) compared with nonusers. This suggests a role for COX-2/ASA in osteoporosis.The purpose of this study was to determine the relationship of nonsteroidal anti-inflammatory drug (NSAID) use, by cyclo-oxygenase selectivity (COX), and aspirin use on bone mineral density (BMD) in participants from the Health, Aging, and Body Composition (Health ABC) population-based cohort. It is known that NSAIDs inhibit the COX enzyme and decrease production of prostaglandins, which are involved in regulation of bone turnover. COX has two isoforms, COX-1 and COX-2. Production of prostaglandins associated with bone loss is primarily mediated through the COX-2 pathway. In addition, aspirin may have effects on bone independent of the prostaglandin pathway.NSAID (by COX selectivity) and aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men: 43.1% black, 56.9% white; mean age: 73.6 years) from the Health ABC cohort. For the purposes of this analysis, relative COX-1 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of > 1 in whole blood, and relative COX-2 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of < 1 in whole blood. Analysis of covariance was used to compare BMD across each NSAID use and aspirin use category adjusting for age, race, gender, weight, height, study site, calcium and vitamin D supplementation, Womac score, history of rheumatoid arthritis, history of arthritis other than rheumatoid, and smoking status.After adjustment for possible confounders, current use of relative COX-2 selective NSAIDs with aspirin was associated with higher BMD at the whole body (4.2%, 1.2-7.3 CI) and total hip (4.6%, 0.5-8.8 CI) by DXA and at both trabecular (34.1%, 15.4-52.7 CI) and cortical spine (12.8%, 2.3-23.3 CI) by quantitative computed tomography.Our data suggest that the combination of relative COX-2 selective NSAIDs and aspirin is associated with higher BMD at multiple skeletal sites in men and women." @default.
• W2093033478 created "2016-06-24" @default.
• W2093033478 creator A5015228664 @default.
• W2093033478 creator A5018378907 @default.
• W2093033478 creator A5021940540 @default.
• W2093033478 creator A5025402303 @default.
• W2093033478 creator A5027298936 @default.
• W2093033478 creator A5046639877 @default.
• W2093033478 creator A5067799201 @default.
• W2093033478 creator A5070153299 @default.
• W2093033478 date "2003-10-01" @default.
• W2093033478 modified "2023-10-16" @default.
• W2093033478 title "Association Between Bone Mineral Density and the Use of Nonsteroidal Anti-Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity" @default.
• W2093033478 cites W1489071669 @default.
• W2093033478 cites W1526826623 @default.
• W2093033478 cites W1544157645 @default.
• W2093033478 cites W1965258941 @default.
• W2093033478 cites W1965629988 @default.
• W2093033478 cites W1981694119 @default.
• W2093033478 cites W1982942836 @default.
• W2093033478 cites W1986290839 @default.
• W2093033478 cites W1986305420 @default.
• W2093033478 cites W1992931986 @default.
• W2093033478 cites W1997364548 @default.
• W2093033478 cites W1997781317 @default.
• W2093033478 cites W2004498172 @default.
• W2093033478 cites W2007362470 @default.
• W2093033478 cites W2008574207 @default.
• W2093033478 cites W2011327495 @default.
• W2093033478 cites W2019370793 @default.
• W2093033478 cites W2019915273 @default.
• W2093033478 cites W2024233889 @default.
• W2093033478 cites W2031059672 @default.
• W2093033478 cites W2032633863 @default.
• W2093033478 cites W2038410983 @default.
• W2093033478 cites W2039358393 @default.
• W2093033478 cites W2043739948 @default.
• W2093033478 cites W2043831621 @default.
• W2093033478 cites W2045133151 @default.
• W2093033478 cites W2051428761 @default.
• W2093033478 cites W2054551985 @default.
• W2093033478 cites W2066074947 @default.
• W2093033478 cites W2071201771 @default.
• W2093033478 cites W2073370113 @default.
• W2093033478 cites W2073501300 @default.
• W2093033478 cites W2078496036 @default.
• W2093033478 cites W2079561092 @default.
• W2093033478 cites W2092927862 @default.
• W2093033478 cites W2107010463 @default.
• W2093033478 cites W2112629831 @default.
• W2093033478 cites W2161113499 @default.
• W2093033478 cites W2321227665 @default.
• W2093033478 doi "https://doi.org/10.1359/jbmr.2003.18.10.1795" @default.
• W2093033478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14584890" @default.
• W2093033478 hasPublicationYear "2003" @default.
• W2093033478 type Work @default.
• W2093033478 sameAs 2093033478 @default.
• W2093033478 citedByCount "128" @default.
• W2093033478 countsByYear W20930334782012 @default.
• W2093033478 countsByYear W20930334782013 @default.
• W2093033478 countsByYear W20930334782014 @default.
• W2093033478 countsByYear W20930334782015 @default.
• W2093033478 countsByYear W20930334782016 @default.
• W2093033478 countsByYear W20930334782017 @default.
• W2093033478 countsByYear W20930334782018 @default.
• W2093033478 countsByYear W20930334782019 @default.
• W2093033478 countsByYear W20930334782020 @default.
• W2093033478 countsByYear W20930334782021 @default.
• W2093033478 countsByYear W20930334782022 @default.
• W2093033478 countsByYear W20930334782023 @default.
• W2093033478 crossrefType "journal-article" @default.
• W2093033478 hasAuthorship W2093033478A5015228664 @default.
• W2093033478 hasAuthorship W2093033478A5018378907 @default.
• W2093033478 hasAuthorship W2093033478A5021940540 @default.
• W2093033478 hasAuthorship W2093033478A5025402303 @default.
• W2093033478 hasAuthorship W2093033478A5027298936 @default.
• W2093033478 hasAuthorship W2093033478A5046639877 @default.
• W2093033478 hasAuthorship W2093033478A5067799201 @default.
• W2093033478 hasAuthorship W2093033478A5070153299 @default.
• W2093033478 hasConcept C126322002 @default.
• W2093033478 hasConcept C134018914 @default.
• W2093033478 hasConcept C181199279 @default.
• W2093033478 hasConcept C185592680 @default.
• W2093033478 hasConcept C2776541429 @default.
• W2093033478 hasConcept C2776886416 @default.
• W2093033478 hasConcept C2777628954 @default.
• W2093033478 hasConcept C2779689624 @default.
• W2093033478 hasConcept C2908647359 @default.
• W2093033478 hasConcept C44249647 @default.
• W2093033478 hasConcept C50382708 @default.
• W2093033478 hasConcept C55493867 @default.
• W2093033478 hasConcept C71924100 @default.
• W2093033478 hasConcept C72563966 @default.
• W2093033478 hasConcept C82789193 @default.
• W2093033478 hasConcept C98274493 @default.
• W2093033478 hasConcept C99454951 @default.
• W2093033478 hasConceptScore W2093033478C126322002 @default.
• W2093033478 hasConceptScore W2093033478C134018914 @default.

• next